{
"id":"mk19_qq_q191",
"number":191,
"bookId":"qq",
"correctAnswer":"A",
"title":"Question 191",
"stimulus":[
{
"type":"p",
"hlId":"c0a00b",
"children":[
"A 35-year-old woman is evaluated for recurrent epigastric pain 8 weeks after completing treatment with amoxicillin, clarithromycin, and omeprazole for a ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Helicobacter pylori"
]
},
"â€“positive duodenal ulcer. The local clarithromycin ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" resistance rate is less than 15%, and the patient was adherent to the medication regimen."
]
},
{
"type":"p",
"hlId":"02028a",
"children":[
"Physical examination and hemoglobin measurement are normal."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"<i>H. pylori</i> stool antigen test"
}
},
{
"letter":"B",
"text":{
"__html":"IgG <i>H. pylori</i> antibody test"
}
},
{
"letter":"C",
"text":{
"__html":"Repeat amoxicillin, clarithromycin, and omeprazole therapy"
}
},
{
"letter":"D",
"text":{
"__html":"Upper endoscopy with duodenal biopsy"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"4f54be",
"children":[
"All patients with ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Helicobacter pylori"
]
},
" infection must be treated and then retested 8 weeks later to document eradication."
]
},
{
"type":"keypoint",
"hlId":"5f451f",
"children":[
"Both the stool antigen test and urea breath test for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Helicobacter pylori"
]
},
" have sensitivities and specificities greater than 95%; the antigen test is widely available and less expensive."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"75c8a8",
"children":[
"The most appropriate next diagnostic test is the ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Helicobacter pylori"
]
},
" stool antigen test (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). All patients with ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" infection must be treated and then retested 8 weeks later to document eradication. Both the stool antigen test and the urea breath test have sensitivities and specificities greater than 95%; the antigen test is widely available and less expensive. ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" is a highly prevalent infection associated with dyspepsia, gastric and duodenal ulcers, gastric adenocarcinoma, and gastric mucosa-associated lymphoid tissue lymphoma. Associations with unexplained iron deficiency and idiopathic thrombocytopenic purpura have been described as well. Several therapeutic regimens (all of which must include a proton pump inhibitor [PPI]) have been found to be effective in the eradication of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori,"
]
},
" including the commonly prescribed macrolide-based triple therapy (clarithromycin, omeprazole, and amoxicillin or metronidazole). This regimen should not be used in patients with documented penicillin allergy, those previously treated with a macrolide, or those who live in an area with a macrolide resistance rate of 15% or greater. In these patients, quadruple bismuth-based therapy (bismuth, tetracycline, PPI, and metronidazole) is recommended. Patients are treated orally for 10 to 14 days. Due to the suppressive effect on ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
", patients should be tested at least 30 days after discontinuing treatment."
]
},
{
"type":"p",
"hlId":"d8ffba",
"children":[
"The presence of IgG ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" antibodies (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") reflects exposure to ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" but not necessarily active infection. IgG ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" antibody testing is not recommended in countries with a prevalence of 30% or less, such as the United States."
]
},
{
"type":"p",
"hlId":"047751",
"children":[
"Repeating triple therapy with amoxicillin, clarithromycin, and omeprazole (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") for recurrent symptoms of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" infection is not appropriate. Instead, quadruple therapy with bismuth subcitrate or subsalicylate, tetracycline, metronidazole, and a PPI is recommended for failure of first-line clarithromycin-based therapy. More importantly, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" infection must be documented before quadruple therapy can be recommended."
]
},
{
"type":"p",
"hlId":"14377b",
"children":[
"Although histologic sampling has a sensitivity greater than 95%, upper endoscopy with biopsy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is usually unnecessary to document ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" infection or eradication in patients younger than 60 years with low risk for malignancy and no alarm symptoms, such as weight loss or anemia."
]
}
],
"relatedSection":"mk19_a_gi_s2_3_4",
"objective":{
"__html":"Evaluate for <i>Helicobacter pylori</i> eradication."
},
"references":[
[
"Chey WD, Leontiadis GI, Howden CW, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112:212-39. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28071659",
"target":"_blank"
},
"children":[
"PMID: 28071659"
]
},
" doi:10.1038/ajg.2016.563"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
},
"hlIds":[
"c0a00b",
"02028a",
"cb2b54",
"4f54be",
"5f451f",
"75c8a8",
"d8ffba",
"047751",
"14377b"
]
}